Trump S New Pharma Tariffs Big Drugmakers Unfazed By 100 Levy But For now, the base case is that generics remain exempt, which limits the direct financial hit to indian pharma. but the risk case, tariffs extending to complex generics or biosimilars, cannot be ruled out. Us president trump announced a 100% tariff on imported branded and patented pharmaceuticals starting october 2025, aiming to boost domestic manufacturing. indian generic drug makers are largely unaffected initially, but concerns loom over potential tariff expansion to complex generics.
What Does Us Import From India Tariffs Could Hit Phones Meds More Indian companies mostly export generic drugs to the u.s., so the likely impact will be pretty minimal, sudarshan jain, an official at the indian pharmaceutical alliance, told cnbc. Indian companies supply around 40% of all generic drugs used in the us. the united states has exempted indian pharmaceutical exports from its newly announced tariffs, ensuring. New us tariffs on branded drugs may disrupt global pharma supply chains, but india’s generic heavy exports remain largely insulated for now. President donald trump introduced sweeping new tariffs on 60 countries, including india, citing high import duties on american goods. while several indian export sectors, including automobiles, it, and jewellery, will face higher levies, pharmaceuticals and other essential items have been spared.
As Trump Threatens Pharmaceutical Tariffs India S Drug Makers Shudder New us tariffs on branded drugs may disrupt global pharma supply chains, but india’s generic heavy exports remain largely insulated for now. President donald trump introduced sweeping new tariffs on 60 countries, including india, citing high import duties on american goods. while several indian export sectors, including automobiles, it, and jewellery, will face higher levies, pharmaceuticals and other essential items have been spared. The united states has announced sweeping new trade measures targeting patented pharmaceutical imports and metals, as president donald trump signed two significant executive actions. under the new framework on thursday, a 100% tariff will apply to patented drug imports from countries, including india, that have neither signed a reshoring agreement with the us commerce department nor a most. Us president donald trump’s latest tariff missile imposing a 100% levy on branded or patented pharmaceuticals is unlikely to have much impact on india’s drug industry that mostly ships. Although the direct impact remains uncertain, the indian pharmaceutical industry could indirectly bear the consequences of us tariffs on chinese goods, which may disrupt supply chains and raise the cost of finished formulations in india. India, the world's pharmacy exporting ~$10.5b in drugs to the us last year (34% of total exports), thrives on low cost generics, not the branded patented segment hit by these tariffs.
What Trump S New Tariffs Mean For Pharmaceuticals And Patented Drugs The united states has announced sweeping new trade measures targeting patented pharmaceutical imports and metals, as president donald trump signed two significant executive actions. under the new framework on thursday, a 100% tariff will apply to patented drug imports from countries, including india, that have neither signed a reshoring agreement with the us commerce department nor a most. Us president donald trump’s latest tariff missile imposing a 100% levy on branded or patented pharmaceuticals is unlikely to have much impact on india’s drug industry that mostly ships. Although the direct impact remains uncertain, the indian pharmaceutical industry could indirectly bear the consequences of us tariffs on chinese goods, which may disrupt supply chains and raise the cost of finished formulations in india. India, the world's pharmacy exporting ~$10.5b in drugs to the us last year (34% of total exports), thrives on low cost generics, not the branded patented segment hit by these tariffs.
Trump Tariffs On Indian Drugs Will Be A Bitter Pill For Americans Although the direct impact remains uncertain, the indian pharmaceutical industry could indirectly bear the consequences of us tariffs on chinese goods, which may disrupt supply chains and raise the cost of finished formulations in india. India, the world's pharmacy exporting ~$10.5b in drugs to the us last year (34% of total exports), thrives on low cost generics, not the branded patented segment hit by these tariffs.
Comments are closed.